However, patients with low-c-Met tumor showed no advantage from tivantinib (median TTP, 1.5 vs. 1.4 months, HR = 0.96, P = 0.92; median OS, 5.0 vs. 9.0 months, HR = 1.33, P = 0.92). The gene discussed is MET; the disease is neoplasm.